What Is Byetta?

1. What is Byetta, and where did it come from?

Byetta is a clear solution of exenatide, a synthetic 39-amino-acid peptide that the label says was originally identified in the Gila monster, Heloderma suspectum. Its sequence only partly overlaps human GLP-1, yet it binds and activates the human GLP-1 receptor. It also holds up far better than the body’s own GLP-1 against the enzymes that break that hormone down, which is what made it usable as a drug; the exenatide page covers that lab work.

FDA approved Byetta for Amylin Pharmaceuticals on April 28, 2005. The original approval letter covered a narrower use than today’s label: people with type 2 diabetes who had not reached their glucose goal on metformin, a sulfonylurea, or both. Later supplements broadened it to the current wording, an adjunct to diet and exercise in adults with type 2 diabetes, including use alone, with a thiazolidinedione, and with basal insulin.

Amylin was bought in 2012 by Bristol-Myers Squibb, with AstraZeneca taking a half share. In December 2013, AstraZeneca agreed to buy out Bristol-Myers Squibb’s share of their diabetes alliance, which gave it sole control of Byetta, the weekly Bydureon and Symlin. By the time it was discontinued, the Byetta label was an AstraZeneca document.

2. How does Byetta work?

The label describes the standard incretin effects of a GLP-1 receptor agonist:

• Insulin when glucose is high. Exenatide increases insulin release only when blood glucose is elevated, which is why it causes little hypoglycemia on its own.
• Less glucagon after meals. It suppresses glucagon when glucose is high, without blocking the glucagon response to a low.
• Slower stomach emptying. Food leaves the stomach more slowly, which flattens the glucose spike after a meal.
• Lower food intake. It reduces appetite, which explains the modest weight loss.

Because Byetta has no fatty-acid chain or slow-release depot, its effect is short. The label gives a terminal half-life of 2.4 hours, with drug measurable for about 10 hours after a dose. That is why Byetta is timed around the two main meals: it works mainly on the glucose rise that follows them. Longer-acting drugs like liraglutide and semaglutide hold steadier levels around the clock; in LEAD-6 (section 6), liraglutide lowered fasting glucose more than Byetta, while Byetta did better after meals. The half-life explainer shows how those curves differ.

3. What is the Byetta dose?

The label’s dosing is short:

The month at 5 mcg is a titration step meant to reduce nausea. Byetta came in two prefilled pens, a 5 mcg pen (300 mcg in 1.2 mL) and a 10 mcg pen (600 mcg in 2.4 mL), each holding 60 doses, or 30 days at two doses a day. Unopened pens were refrigerated; after first use a pen could be kept at up to 77°F (25°C) and was discarded 30 days later even if drug remained. The label also warns that pens must never be shared, even with a new needle, because of the risk of passing on blood-borne infections.

These are the labeled doses, given for reference. They are not a recommendation for anyone.

4. What did the Byetta trials show?

Byetta’s approval rested on three 30-week, placebo-controlled trials in people already taking oral diabetes drugs. Each was also published separately: Buse 2004 with a sulfonylurea, DeFronzo 2005 with metformin, and Kendall 2005 with both. HbA1c is a blood test that reflects average glucose over about three months. The label’s results for the 10 mcg dose:

Baseline HbA1c in these trials ran from 8.2% to 8.7%. Later trials on the label filled in other uses:

Two results stand out. First, Byetta could match insulin on HbA1c while moving weight in the other direction. In an open-label trial by Heine and colleagues, 551 people on metformin and a sulfonylurea got either Byetta 10 mcg twice daily or insulin glargine. HbA1c fell 1.11 points in both groups, while weight fell 2.3 kg on Byetta and rose 1.8 kg on glargine. Nausea was the price: 57.1% versus 8.6%.

Second, the effect lasted in those who stayed on it. In an 82-week open-label extension of the metformin trial, the 92 people who completed 82 weeks had an HbA1c reduction of 1.3 points and weight loss of 5.3 kg from baseline. Extensions like this keep only the people who tolerate and benefit from the drug, so they flatter the result.

5. Does Byetta cause weight loss?

Some, but it was never approved for weight loss. In the diabetes trials above, the 10 mcg dose produced 1.6 to 2.9 kg of weight loss over 24 to 30 weeks.

The one controlled trial in people without diabetes was small. Rosenstock and colleagues randomized 152 adults with obesity (average BMI 39.6) to exenatide or placebo for 24 weeks, both alongside a lifestyle program. Weight fell 5.1 kg on exenatide versus 1.6 kg on placebo, a placebo-subtracted difference of 3.3% of body weight. For scale, Wegovy and Zepbound are labeled for chronic weight management, and their trials produced much larger losses. Byetta’s weight effect was a side benefit of a diabetes drug, not its purpose.

No trial reviewed for this page measured body composition on Byetta, so how much of the loss was fat versus lean mass is not established. The general question is covered in GLP-1 drugs and muscle loss.

6. How does Byetta compare with newer GLP-1 drugs?

Byetta was the comparator that later drugs had to beat, and they mostly did:

In LEAD-6, once-daily liraglutide, later sold as Victoza, lowered fasting glucose more, while Byetta did slightly better on the glucose rise after breakfast and dinner, consistent with its short, meal-timed action. Byetta was also the comparator in the GetGoal-X trial of lixisenatide, sold as Adlyxin, another short-acting GLP-1 drug. No head-to-head trial of Byetta against tirzepatide or weekly semaglutide turned up in the sources reviewed.

7. What are Byetta’s side effects?

Stomach symptoms dominate. In the three 30-week add-on trials on the label, with 963 people on Byetta and 483 on placebo:

Nausea rose with dose and, in most people, became less frequent and less severe over time. Nausea led 3% to stop and vomiting 1%.

Low blood sugar depends on the other drugs

Byetta’s glucose-dependent action keeps hypoglycemia rare when it is used alone or with metformin. Paired with a drug that forces insulin release regardless of glucose, the picture changes:

The label advises that a lower sulfonylurea or insulin dose may be needed when Byetta is added.

Antibodies

Most people develop some antibodies to exenatide. In the 30-week add-on trials, 38% had low-titer antibodies and 6% higher-titer antibodies at week 30, and about 3% overall had a weaker glucose response because of them. The rarer and more dangerous immune effect is described in the next section.

8. What warnings and contraindications does the label carry?

Byetta has no boxed warning. The thyroid C-cell tumor warning carried by most weekly GLP-1 drugs, including Bydureon, does not appear on Byetta’s label. The label’s contraindications are a prior severe allergic reaction to exenatide or the product’s ingredients, and a history of drug-induced immune thrombocytopenia from any exenatide product.

The warnings section lists:

• Acute pancreatitis, including fatal hemorrhagic or necrotizing cases, seen across the GLP-1 class. Byetta is stopped if pancreatitis is suspected.
• Acute kidney injury from dehydration, sometimes needing dialysis, mostly in people with vomiting or diarrhea. Byetta is not recommended when creatinine clearance is below 30 mL/min or in end-stage kidney disease.
• Severe stomach side effects. Byetta is not recommended in severe gastroparesis.
• Drug-induced immune thrombocytopenia, an antibody reaction that destroys platelets and can cause fatal bleeding. Anyone who has had it must not take exenatide again.
• Serious allergic reactions, including anaphylaxis and angioedema.
• Gallbladder disease: 1.9% on exenatide versus 1.4% on placebo had an acute gallbladder event in a clinical study.
• Aspiration under anesthesia or deep sedation, because food can stay in the stomach longer.

Byetta’s effect on stomach emptying also slows the absorption of pills. The label’s drug-interaction data show reduced peak levels of acetaminophen and of oral contraceptives taken shortly after a dose, and it advises taking oral contraceptives and antibiotics at least 1 hour before Byetta. Safety and effectiveness were not established in children: a trial in 120 people aged 10 to 17 did not show that Byetta worked. Data in pregnancy are limited, and animal studies showed fetal harm, so the label limits use to cases where the benefit justifies the risk.

9. Was Byetta discontinued?

Yes, in both the US and the EU. Here is the record, checked on November 8, 2026:

Drugs@FDA lists both Byetta pens as discontinued, and FDA’s drug shortage database shows exenatide injection with the status “Discontinuation.” The insurer notice gave no reason for the US discontinuation; the EMA record states AstraZeneca’s reason in Europe as commercial, not safety.

The generic’s status needs care. The NDC Directory still listed the Amneal pens in November 2026, with marketing end dates of May 31 and June 30, 2027. FDA’s NDC definitions say that when a product is no longer being manufactured, firms are asked in most cases to use the expiration date of the last lot as that end date. Read together, the records suggest manufacturing has stopped and remaining stock is running out, but they are not a pharmacy inventory. Amneal had not posted a public discontinuation notice that could be found when this page was written. Anyone still using exenatide should ask their pharmacy about supply and talk with their prescriber about alternatives before running out.

10. What replaced Byetta, and what should a log capture?

The insurer notices that followed the discontinuation pointed members to other GLP-1 drugs, including Ozempic, Trulicity, Mounjaro, Rybelsus and liraglutide. Those are weekly, daily or oral options with different trial records, and choosing among them is a prescriber’s job. The weekly version of the same molecule, Bydureon, was discontinued at the same time.

For anyone tracking Byetta or the generic, the label points to what matters: the time of each injection relative to the meal that follows, the dose (5 or 10 mcg), the date each pen was first used (it is discarded after 30 days), nausea, and any low glucose readings if a sulfonylurea or insulin is in the mix. Unusual bruising or bleeding needs prompt medical attention because of the platelet risk. Because Byetta clears within about a day, a change after switching to a weekly drug is more likely to reflect the new drug than leftover exenatide, unlike switches off a weekly depot. How GLP-1 tracking works covers what to record, and how long GLP-1 drugs stay in your system compares washout times.

11. Byetta FAQ

• Is Byetta still available?

  Not as a brand in the US. A UnitedHealthcare provider notice dated December 19, 2024 says AstraZeneca discontinued Byetta on October 25, 2024, and Drugs@FDA lists both Byetta pens as discontinued. Amneal launched an AP-rated generic exenatide pen in 2025, but when checked on November 8, 2026, Drugs@FDA listed that generic as discontinued too. The NDC Directory still showed marketing end dates in 2026 and 2027, which usually track the expiry of the last lots. Whether a pharmacy can fill it is a question for the pharmacy and prescriber.

• What is the Byetta dose?

  The label starts at 5 mcg injected under the skin twice daily, within the 60 minutes before the morning and evening meals or the two main meals of the day at least about 6 hours apart. After one month the dose can go up to 10 mcg twice daily based on clinical response. It is never injected after a meal.

• Is Byetta the same as Bydureon?

  Same molecule, different product. Byetta is a plain exenatide solution injected twice a day. Bydureon and Bydureon BCise put exenatide into slow-release microspheres for once-weekly dosing, which changes the side-effect profile and adds a boxed thyroid warning that Byetta does not carry.

• Does Byetta cause weight loss?

  Modestly. In the label's trials, weight fell 1.6 to 2.9 kg on the 10 mcg dose over 24 to 30 weeks. In a 24-week trial in adults with obesity but no diabetes, exenatide plus lifestyle change produced 5.1 kg of loss versus 1.6 kg on placebo. Byetta was never approved for weight loss.

• What are the most common side effects of Byetta?

  Nausea, vomiting and diarrhea. In the three 30-week add-on trials, nausea affected 44% of people on Byetta versus 18% on placebo, vomiting 13% versus 4%, and diarrhea 13% versus 6%. Nausea usually eased with continued use; 3% stopped because of it.

• Does Byetta cause low blood sugar?

  Rarely on its own or with metformin, but often with a sulfonylurea. In the label's sulfonylurea add-on trial, 35.7% of people on the 10 mcg dose had hypoglycemia versus 3.3% on placebo, which is why the label suggests lowering the sulfonylurea or insulin dose.

• Does Byetta have a boxed warning?

  No. Byetta's label has no boxed warning. The thyroid C-cell tumor boxed warning applies to the weekly exenatide products, Bydureon and Bydureon BCise, not to twice-daily Byetta.

• Can I switch from Byetta to another GLP-1 drug?

  That is a prescriber decision. Byetta's 2.4-hour half-life means it clears within about a day, so the timing differs from switching off a weekly drug. Insurer notices issued after the 2024 discontinuation pointed members to other GLP-1 drugs such as Ozempic, Trulicity, Mounjaro and liraglutide.

12. Sources